Internal Medicine | Page 134 of 487 | Links Medicus Content Curation & Alerts in Medicine

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

Meta-analysis finds the overall prevalence of statin intolerance is around 9% and identifies the most common risk factors.

17 Feb, 2022 | 10:07h | UTC

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Commentaries:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

Commentary on Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3 @escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022

Review: Diagnosis and treatment of acute coronary syndromes.

17 Feb, 2022 | 10:04h | UTC

Diagnosis and Treatment of Acute Coronary Syndromes: A Review – JAMA (free for a limited period)

Audio clinical review: Diagnosis and Treatment of Acute Coronary Syndromes – JAMA

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia.

17 Feb, 2022 | 10:01h | UTC

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia – Internal and Emergency Medicine

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

Perspective | The hidden epidemic: Antibiotic resistance is approaching a crisis point, and the world needs to act.

17 Feb, 2022 | 08:39h | UTC

The Hidden Epidemic – Vox

Cohort Study: Depressed symptomatology persists over time in systemic lupus erythematosus patients.

17 Feb, 2022 | 08:15h | UTC

Depressed Symptomatology Persists Over Time in Systemic Lupus Erythematosus Patients – Arthritis Care & Research

Commentary: Depression persists in most lupus patients despite therapies, changes in disease activity – Healio (free registration required)

Time for united action on depression: a Lancet–World Psychiatric Association Commission.

16 Feb, 2022 | 10:18h | UTC

Homepage: Time for united action on depression: a Lancet–World Psychiatric Association Commission – The Lancet

Editorial: Ensuring care for people with depression (free registration required)

Commission: Time for united action on depression: a Lancet–World Psychiatric Association Commission (free registration required)

News Release: Overlooked and underfunded—experts call for united action to reduce the global burden of depression – The Lancet

Commentary on Twitter

Depression is overlooked & underfunded.

New Lancet-@WPA_Psychiatry Commission calls for whole-of-society approach to alleviate one of the world's leading causes of avoidable suffering & premature deaths. #UniteAgainstDepression

➡️ https://t.co/0NxPbhGAlY pic.twitter.com/b4nG9YvbaH

— The Lancet (@TheLancet) February 15, 2022

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

16 Feb, 2022 | 10:13h | UTC

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review – The Lancet Global Health

Commentary on Twitter

A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig

— Eric Topol (@EricTopol) February 15, 2022

WHO guideline on control and elimination of human schistosomiasis.

16 Feb, 2022 | 10:11h | UTC

WHO guideline on control and elimination of human schistosomiasis – World Health Organization

Development of a metric to detect and decrease low-value prescribing in older adults.

16 Feb, 2022 | 09:58h | UTC

Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults – JAMA Network Open

Invited Commentary: Considering Value in Prescribing and Deprescribing for Older Adults – JAMA

Commentary on Twitter

In this qualitative study, a scientifically valid and clinically useful low-value prescribing metric was built. EVOLV-Rx may enhance the detection of low-value prescribing practices, reduce polypharmacy, and enable older adults to receive high-value care. https://t.co/GtrsUboT9o

— JAMA Network Open (@JAMANetworkOpen) February 15, 2022